LAVIPHARM S.A. NA EO 1 (BXA0) — Capital Reinvestment Ratio

Latest as of December 2024: 2.08x

LAVIPHARM S.A. NA EO 1 (BXA0) has a Capital Reinvestment Ratio of 2.08x as of December 2024, meaning it reinvests 2% of its operating cash flow (€4.64 Million) in capital expenditures (€9.64 Million). See BXA0 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

2.08x
Capex / Operating Cash Flow

Operating Cash Flow

€4.64 Million
EUR

Capital Expenditures

€9.64 Million
EUR

Data as of

Dec 2024
Most recent filing

LAVIPHARM S.A. NA EO 1 Capital Reinvestment Ratio (2021–2024)

This chart tracks LAVIPHARM S.A. NA EO 1's Capital Reinvestment Ratio across 4 annual periods. Check LAVIPHARM S.A. NA EO 1 (BXA0) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for LAVIPHARM S.A. NA EO 1 (2021–2024)

Year-by-year Capital Reinvestment Ratio for LAVIPHARM S.A. NA EO 1 from 2021 to 2024. For live market cap and broader valuation context, see how much is LAVIPHARM S.A. NA EO 1 worth.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2024 2.08x €4.64 Million €9.64 Million ▼ -85.4%
2023 14.26x €284.00K €4.05 Million ▲ +33.9%
2022 10.64x €3.35 Million €35.62 Million ▲ +2181.6%
2021 0.47x €4.11 Million €1.92 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow